Recent studies show that cardiovascular mortality can become the leading cause of death in cancer survivors over the years. New data on ICI myocarditis, landmark cardioprotection trials and the first comprehensive JACC expert panel are redefining the field. Oncology has made breathtaking progress over the past two decades: 18.1 million cancer survivors in the US alone (as of 2022), rising to 21.6 million by 2030. However, this therapeutic success story has a cardiovascular downside. Cancer therapies can damage the myocardium, attack the vascular walls, trigger arrhythmias and provoke heart failure – and cardiovascular disease is the leading non-cancer cause of death in cancer survivors. Cardio-oncology as an independent specialty responds to this dilemma with integrated care models, refined risk stratification and a growing evidence base for targeted prevention and therapy.
Jetzt beitreten
